Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery
NCT04244981 · SHI Jia · PHASE4 · terminated · last registry update 2026-06-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “At a meeting on February 17, 2025, the Data and Safety Monitoring Board recommended early termination because the predefined efficacy boundary was crossed.” | – | Registry record, SHI Jia |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F7 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Results posted on the registry: University of Maryland, Baltimore, Kcentra + Frozen Plasma Product, Human (NCT03341156)
- 2026-11-10Also stopped (terminated): University of Maryland, Baltimore, Kcentra + Frozen Plasma Product, Human (NCT03341156)
- 2026-11-09Phase 3 first posted: Pfizer, marstacimab (NCT07923981)
- 2026-11-09Results posted on the registry: Octapharma, a drug against F7 (NCT03320603)
- 2026-11-06Also stopped (withdrawn): Emory University, Emicizumab + FEIBA (NCT04563520)
- 2026-10-21Also stopped (terminated): University Health Network, Toronto, Fibrinogen + PCC + Frozen Plasma (NCT04534751)
- 2026-10-05Also stopped (terminated): Pfizer, PF-06838435 (formerly SPK-9001) (NCT03307980)
- 2026-08-14Results posted on the registry: Pfizer, PF-06741086 (NCT03938792)
- 2026-07-31Results posted on the registry: Laboratoire français de Fractionnement et de Biotechnologies, Coagulation Factor VIIa (Recombinant) (NCT05695391)
- 2026-07-31Also stopped (terminated): Laboratoire français de Fractionnement et de Biotechnologies, Coagulation Factor VIIa (Recombinant) (NCT05695391)
- 2026-07-31Results posted on the registry: Spur Therapeutics, verbrinacogene setparvovec (NCT05164471)
- 2026-07-31Also stopped (terminated): Spur Therapeutics, verbrinacogene setparvovec (NCT05164471)
- 2026-07-24Also stopped (terminated): AstraZeneca, Ceralasertib + Drug X (NCT06929260)
- 2026-06-25Also stopped (terminated): Octapharma, Octaplex (NCT04867837)
- 2025-12-10Also stopped (terminated): CSL Behring, BE1116 + Placebo (NCT05568888)
- 2025-11-12Phase 3 first posted: Joseph Broderick, MD, Recombinant Factor VIIa + Biological/Vaccine: Placebo (NCT07227246)
- 2025-11-10Results posted on the registry: CSL Behring, BE1116 + Placebo (NCT05568888)
- 2025-11-06Results posted on the registry: Pfizer, Standard of Care FIX Replacement therapy + Standard of Care FVIII Replacement therapy (NCT03587116)
- 2025-08-15Results posted on the registry: Octapharma, Octaplex + Frozen Plasma Product, Human (NCT05523297)
- 2025-07-30Phase 3 first posted: CSL Behring, BE1116 + FFP (NCT07094087)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision